Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

Genmab reported confirmed and unconfirmed objective response rates for investigational petosemtamab of 75% in first-line and 67% in second-line metastatic colorectal cancer, at median follow-ups of 5.9 and 7.1 months, respectively. The first-line ORR was 81% among patients with left-sided tumors. The updated Phase 2 analyses support ongoing global Phase 3 trials, which are actively enrolling.

Analysis

The investable question is whether these response rates translate into a durable, clinically meaningful advantage over current regimens—not whether the early signal looks strong. Short follow-up, inclusion of unconfirmed responses, and the absence here of sample sizes, control-arm data, duration-of-response detail, or safety comparisons materially limit what can be inferred. The 1L left-sided result may support a focused development opportunity, but it should not be extrapolated to right-sided disease or treated as evidence of broad mCRC benefit.

For Genmab, the read-through is positive but still largely a Phase 3 option: confirmatory efficacy and tolerability must survive a much larger dataset before changing revenue expectations. Pairing with established chemotherapy could ease clinical adoption if benefit is confirmed; conversely, added toxicity or treatment burden could constrain use even with encouraging response rates. Competitors with established mCRC regimens retain the advantage until comparative outcomes and a usable patient-selection profile emerge.

Near term, the release may support sentiment, but the 1–3 month catalysts are fuller trial design and safety disclosures, enrollment progress, and any further durability data. Over 6–18 months, Phase 3 readouts are the potential valuation driver; timing and endpoint details are not provided. The contrarian risk is assuming ORR will predict survival or displace existing treatment. No valuation or positioning data are supplied, so a large directional trade is not justified.

Key Decisions for Investors

• Treat as a modestly positive catalyst for GMAB, not a Phase 3 de-risking event; avoid extrapolating the reported ORRs into sales or peak-market estimates.
• Keep GMAB on a catalyst watchlist and verify patient counts, confirmed-only response rates, duration of response, grade 3+ toxicity, discontinuations, trial comparators, endpoints, and expected readout timing before adding exposure.
• For an event-driven position, prefer limited-risk exposure over an outright concentrated long until trial design and valuation are assessed. No specific entry level is supportable from the supplied information.
• Falsify the positive thesis if subsequent data show materially weaker confirmed responses, short-lived benefit, problematic toxicity, enrollment delays, or Phase 3 design that cannot establish an advantage over relevant standard therapy.